文献速递艾滋病与性传播感染

CD4/CD8比值与有效治疗HIV感染中卡波西肉瘤或非霍奇金淋巴瘤风险:20项欧洲队列研究的协作分析

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.
PubMed 文献 · Clin Infect Dis · 2021-01-01

结果显示低CD4/CD8比值与KS风险增加相关(HR=2.02),高CD8计数与NHL风险增加相关(HR=3.14),在CD4≥500/mm3者中关联更强。

要点

  • 低CD4/CD8比值(0.3 vs 1)与KS风险增加相关(HR=2.02)。
  • 高CD8计数(3000 vs 1000/mm3)与NHL风险增加相关(HR=3.14)。
  • CD4≥500/mm3者中上述关联更强(KS HR=3.27,NHL HR=5.28)。

核心结论

  • 有效cART下低CD4/CD8比值和高CD8计数分别与KS和NHL风险增加相关,尤其在CD4≥500/mm3者中。

主要发现

  • 病毒学控制时CD4计数中位数414(IQR 296-552)/mm3,CD8计数936(IQR 670-1304)/mm3,CD4/CD8比值0.43(IQR 0.28-0.65)。
  • 共诊断221例KS和187例NHL,分别发生于病毒学控制后9(IQR 2-37)和18(IQR 7-42)个月。
  • 低CD4/CD8比值(0.3 vs 1)与KS风险相关(HR=2.02,95%CI 1.23-3.31),与NHL风险无显著关联。
  • 高CD8计数(3000 vs 1000/mm3)与NHL风险相关(HR=3.14,95%CI 1.58-6.22)。
  • CD4≥500/mm3者中关联增强:KS HR=3.27(95%CI 1.60-6.56),NHL HR=5.28(95%CI 2.17-12.83)。

临床怎么用

  • 对有效cART的HIV感染者,可考虑监测CD4/CD8比值和CD8计数以评估KS/NHL风险。
  • CD4≥500/mm3者若CD4/CD8比值低或CD8计数高,仍应警惕KS/NHL风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH. METHODS: PLWH from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) were included if they achieved virological control (viral load ≤ 500 copies/mL) within 9 months following cART and without previous KS/LNH diagnosis. Cox models were used to identify factors associated with KS or NHL risk, in all participants and those with CD4 ≥ 500/mm3 at virological control. We analyzed the CD4/CD8 ratio, CD4 count and CD8 count as time-dependent variables, using spline transformations. RESULTS: We included 56 708 PLWH, enrolled between 2000 and 2014. At virological control, the median (interquartile range [IQR]) CD4 count, CD8 count, and CD4/CD8 ratio were 414 (296-552)/mm3, 936 (670-1304)/mm3, and 0.43 (0.28-0.65), respectively. Overall, 221 KS and 187 NHL were diagnosed 9 (2-37) and 18 (7-42) months after virological control. Low CD4/CD8 ratios were associated with KS risk (hazard ratio [HR] = 2.02 [95% confidence interval {CI } = 1.23-3.31]) when comparing CD4/CD8 = 0.3 to CD4/CD8 = 1) but not with NHL risk. High CD8 counts were associated with higher NHL risk (HR = 3.14 [95% CI = 1.58-6.22]) when comparing CD8 = 3000/mm3 to CD8 = 1000/mm3). Similar results with increased associations were found in PLWH with CD4 ≥ 500/mm3 at virological control (HR = 3.27 [95% CI = 1.60-6.56] for KS; HR = 5.28 [95% CI = 2.17-12.83] for NHL). CONCLUSIONS: Low CD4/CD8 ratios and high CD8 counts despite effective cART were associated with increased KS/NHL risks respectively, especially when CD4 ≥ 500/mm3.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Caby F, Guiguet M, Weiss L, et al. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clin Infect Dis. 2021. PMID: 34370842. doi:10.1093/cid/ciaa1137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。